Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERCC1-directed cetuximab plus chemotherapy in untreated wild-type RAS metastatic colorectal cancer
2011-003217-41Phase 2Completed
- Sponsor
- AGMT
- Start
- Dec 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab, oxaliplatin, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC) (2 arms), sponsored by AGMT. Primary endpoint: Objective response rate. Started Dec 2011; status: completed.
02
Drugs
cetuximaboxaliplatinirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2011-003217-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003217-41.